SGLT2-Is vs. placebo reduced the risk of the composite outcome of CVD death/HF hospitalisation in White (n = 4 studies) and Asian (n = 2 studies), with no strong evidence of an effect in Black (n = 3 studies) and Other (n = 2 studies) populations: HRs (95% CIs) of 0.76 (0.65–0.90), 0.61 (0.42–0.89), 0.74 (0.49–1.13) and 0.77 (0.12–5.02), respectively (Supplementary Appendix 6). The gene discussed is SLC5A2; the disease is hydrops fetalis.